Harold Lee

Harold Lee is Vice President of Finance at HealthQuest Capital, a healthcare-focused growth equity firm headquartered in Redwood City, California. He joined the firm in 2017 and brings more than 20 years of finance and accounting experience across public accounting, corporate finance, and advisory roles. His firm bio highlights expertise in developing complex economic valuation models, serving as a financial advisor, and operations management.

Harold began his career in public accounting at Deloitte in San Francisco, where he completed the requirements for his CPA licensure (California, now inactive). He subsequently held roles at Exxon Mobil — where he helped develop the company's online business program during the early "dot-com" era — and at AlixPartners, where he specialized in operational and financial due diligence, litigation consulting, and forensic accounting. His background also includes time at Wells Fargo. Prior to HealthQuest, he served as CFO of a privately held residential mortgage lending and loan-servicing company originating over $6 billion in loans annually.

He holds a Bachelor of Science in Accounting from the University of San Francisco and a Master of Science from Carnegie Mellon University (Tepper School of Business / School of Computer Science, in electronic commerce). His professional credentials include Certified Public Accountant (inactive, California), plus certifications in Insolvency & Restructuring Advisory, Financial Forensics, and Fraud Examination.

Note: Harold's role is a firm finance/operations leadership position rather than an investment-partner (deal-sourcing, check-writing) role. The stub description of him as an "angel investor" writing seed-round checks does not match verifiable public information; HealthQuest Capital is a growth-stage healthcare investor.

The following reflects HealthQuest Capital's firm strategy (Harold's employer), since Harold serves in a finance leadership capacity rather than as an investing partner:

• Invests in commercial-stage / growth-stage healthcare companies — not seed or angel-stage deals.
• Sector focus spans medical devices, biopharma, healthcare services, and healthcare IT.
• Targets companies with strong "commercial prospects that drive enhanced patient outcomes and elevate the efficiency of healthcare delivery."
• Deploys capital from sizable dedicated funds: Fund II (2016, $228M), Fund III (2019, $447M), Fund IV (2022, $685M), and a Tactical Opportunities Fund (2023, $310M) — managing roughly $2 billion in total capital.
• Portfolio-level impact metrics cited by the firm include ~104M patients reached, 3,000+ hospital partners, and ~6,500 employer partners.